14 02, 2019 Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition Diatech Pharmacogenetics2020-01-22T12:34:32+01:00 Read More